← 治験一覧に戻る
HER2陽性早期乳がんにおけるCT-P6の有効性および安全性評価試験
基本情報
- NCT ID
- NCT02162667
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 562
- 治験依頼者名
- Celltrion
概要
This study will determine whether CT-P6 and Herceptin are equivalent in patients with early-stage breast cancer undergoing neoadjuvant chemotherapy. Our hypothesis is that the pathologic complete response rate will be equivalent in patients treated with neoadjuvant CT-P6 or Herceptin. Patients will receive 8 cycles of neoadjuvant systemic therapy and up to 10 cycles of therapy in the adjuvant setting.
対象疾患
HER2-positive Carcinoma of Breast
介入
Trastuzumab(DRUG)